Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DIA03-NTB
- Development stage
- Preclinical
- Lead developer
- Dianosic
- Administration
- Intranasal
01
Overview
DIA03-NTB is an exploratory, preclinical-stage drug delivery program developed by Dianosic. It utilizes a specialized intranasal insert designed for nose-to-brain (NTB) delivery, leveraging the company's proprietary polymer elution technology derived from its DIA01-R platform. The system is intended to provide sustained release of therapeutic agents directly to the central nervous system, bypassing the blood-brain barrier. While the specific active pharmaceutical ingredients have not been publicly disclosed, the program is currently targeting the treatment of neurological and psychiatric conditions, specifically schizophrenia and Parkinson's disease.
Beyond the preview
Go deeper on DIA03-NTB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIA03-NTB.